DNA-scaffolded biomaterials enable modular and tunable control of cell-based cancer immunotherapies

Xiao Huang; Jasper Z. Williams; Ryan Chang; Zhongbo Li; Eric Gai; David M. Patterson; Yu Wei; Wendell A. Lim; Tejal A. Desai

The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/587105 doi: bioRxiv preprint addition of 2.5 x 10 4 CD8+ T cells and AICE at 0.075 OD550 x 200 μL final (unless otherwise specified). After 1-3 days, cells were gently washed with PBS for 2 times, and analyzed for cell viability using PrestoBlue Cell Viability Reagent (Invitrogen #A13262). In vivo tumor targeting NSG mice (Jackson Laboratory #005557, female, ~8-12weeks old) were implanted with two identical xenograft tumors -5 x 10 6 HER2+ K562 tumor cells subcutaneously on the left and right flank. Seven days after tumor implantation, human primary CD4+ (4 x 10 6 ) and CD8+ T cells (4 x 10 6 ) were injected intravenously into the tail vein of the mice. These T cells were either untransduced (control) or engineered with the anti-GFP synNotch Gal4VP64 receptor and the corresponding response elements regulating anti-HER2 4-1BBζ CAR expression. On the same day, AICE-GFP particles were injected intratumorally at one All rights reserved. No reuse allowed without permission.